Business Context and Reporting Period
This Form 8-K Current Report is filed by Neuralstem, Inc. (not Palisade Bio, Inc., as indicated in the metadata) for the period ending September 10, 2013, with the earliest event reported on September 4, 2013. The filing details the entry into a material definitive agreement regarding a private placement offering of securities.
Key Financial Metrics
The filing discloses specific capital raise metrics but does not provide general operating financials such as revenue, profit, or cash flow.
- Gross Proceeds: $4,556,000
- Net Proceeds: Estimated at $4,243,000 (after deducting fees and expenses)
- Placement Agent Fee: $273,360 (6% of gross proceeds)
- Placement Agent Expense Reimbursement: $15,000
- Units Sold: 2,847,500 units at $1.60 per unit
- Shares Issued: 2,847,500 shares of common stock
- Warrants Issued: 1,423,750 warrants to purchase 0.5 share each at $2.00 exercise price
Material Changes
The primary material change is the execution of securities purchase agreements with accredited investors on September 4 and September 9, 2013. This transaction results in the issuance of new equity and warrants, increasing the company's share count and potential future dilution upon warrant exercise. The filing does not provide comparative data to prior periods as it is a transaction-specific report.
Outlook, Risks, and Unusual Items
Transaction Terms: The offering closed on or about September 10, 2013. Warrants are exercisable six months after issuance with a five-year term. The Placement Agent received a warrant to purchase up to 170,850 shares (6% of shares issued) with an exercise price of $2.00, terminating on October 14, 2015.
Risks and Contingencies: The filing notes that the warrants contain adjustment provisions for stock splits, dividends, and fundamental transactions but explicitly state they do not contain "price protection provisions" regarding subsequent securities issuances. The transaction is subject to customary closing conditions.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received versus the estimated $4,243,000.
- Confirm the updated total share count and fully diluted share count including the new warrants.
- Review the Prospectus Supplements filed on September 6 and September 10, 2013, for specific use of proceeds.
- Monitor the exercise of the 1,423,750 investor warrants and the 170,850 placement agent warrants starting six months post-issuance.